As many patients already know, urinary tract infections (UTIs) can recur despite the use of antibiotics.
So, it's welcome news that the U.S. Food and Drug Administration on Wednesday approved Pivya to fight bacterial
"The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs," he added.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves New Antibiotic for Uncomplicated UTIsThe US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
Read more »
FDA Approved New Antibiotic Against UTIsAs many patients already know, urinary tract infections (UTIs) can recur despite the use of antibiotics. So, it's welcome news that the U.S. Food and Drug Administration on Wednesday approved Pivya (pivmecillinam) to fight bacterial UTIs. 'UTIs are a very common condition...
Read more »
FDA Approves New Bladder Cancer DrugThe first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.
Read more »
FDA Approves Danicopan as Add-On Therapy for Hemolysis TreatmentThe US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab orPNH is a rare blood disorder affecting 1-10 individuals per million. The condition, which eliminates red blood cells and leads to blood clots and impaired bone marrow function, can cause life-threateningRavulizumab and eculizumab, also both made by AstraZeneca, inhibit the destruction of red blood cells. However, 10%-20% of patients treated with the antibody infusions experience significant extravascular hemolysis, in which these surviving red blood cells are eliminated by the spleen and liver. Extravascular hemolysis can lead to ongoing anemia, which can lead patients to require blood transfusions. Danicopan, an investigational, first-in-class, oral complement factor D inhibitor, is designed to control intravascular hemolysis and prevent extravascular hemolysis
Read more »
FDA Approves TriClip for Tricuspid RegurgitationThe FDA has approved the use of TriClip for the treatment of tricuspid regurgitation. The decision was based on the results of a randomized controlled trial, which showed that patients who underwent repair with the TriClip system experienced a significant reduction in valve dysfunction and improvement in quality of life. The procedure was found to be safe, with a low rate of major adverse events.
Read more »
FDA Approves Iloperidone for Bipolar DisorderThe US Food and Drug Administration has approved iloperidone tablets (Fanapt) for the treatment of bipolar disorder in adults.
Read more »